Clinical Neurology NewsSiponimod shows promise through 24 months in relapsing-remitting MSJuly 5, 2016Multiple Sclerosis
Neurology ReviewsOcrelizumab May Be More Effective for Relapsing-Remitting MS Than InterferonJune 28, 2016Multiple Sclerosis
Neurology ReviewsChoosing MS Treatments From the Therapeutic ArmamentariumJune 28, 2016Multiple Sclerosis
Clinical Neurology NewsReal-world MS relapse rate is low for dimethyl fumarateJune 15, 2016Multiple Sclerosis
Clinical Neurology NewsAlemtuzumab beneficial for MS patients of African descentJune 15, 2016Multiple Sclerosis
Clinical Neurology NewsExercise improves sleep and may improve cognitive/physical function in MSJune 15, 2016Multiple SclerosisSleep Medicine
Clinical Neurology NewsReal-world data favor dimethyl fumarate, fingolimod for MSJune 14, 2016Multiple Sclerosis
Clinical Neurology NewsOral contraceptive efficacy unaffected by dimethyl fumarateJune 11, 2016Multiple Sclerosis
Clinical Neurology NewsTeriflunomide effective for faster-advancing MSJune 10, 2016Multiple Sclerosis
Neurology ReviewsConnecting Health Care Providers With Patients Through Mobile TechnologyJune 7, 2016Multiple Sclerosis
Neurology ReviewsDisability Improves or Stabilizes Over Eight Years of Fingolimod TreatmentJune 7, 2016Multiple Sclerosis
